Addex moves R&D operations to Campus Biotech in Geneva
To advance its portfolio of allosteric modulator drug candidates
Addex Therapeutics, a Swiss developer of allosteric modulators for neurological disorders, has moved its R&D operations to the Campus Biotech, a new life sciences centre of excellence located at the former Merck Serono site in Geneva.
Campus Biotech provides an environment for scientists and entrepreneurs to translate ideas into products that will have an impact on society and the world, the firm said.
Spanning 40,000m2, the centre welcomes academic and industrial partners, including teams from EPFL (the Lausanne-based Swiss Federal Institute of Technology), UNIGE (University of Geneva), the University Hospitals of Geneva, the Wyss Centre of bio- and neuro-engineering, the Human Brain Project, the Swiss Institute of bioinformatics, and the HEPIA, which is part of the HES-SO (University of Applied Sciences Western Switzerland), come together.
'Joining the centre of excellence in life science and in particular neuroscience that is being created at the Campus Biotech will provide Addex with access to multiple cutting edge scientific platforms,' said Tim Dyer CEO at Addex.
'We believe that being part of the Campus's blend of science and industry is the perfect environment for Addex to excel as we execute on our strategy to advance our portfolio of allosteric modulator drug candidates.'
